找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Cancer Management in Man; Biological Response Paul V. Woolley Book 1989 Kluwer Academic Publishers 1989 Tumor.antibiotics.biology.bone mar

[復制鏈接]
樓主: STRI
21#
發(fā)表于 2025-3-25 05:46:35 | 只看該作者
Background on User-Defined Routines,0 and P388 leukemias, and human mammary and colon xenographs, among others (212). In addition, DDP was found to be active by several treatment schedules, against rat as well as mouse tumors, and to be active against tumors of both chemical and biological origins (169). Clinical trials of DDP first b
22#
發(fā)表于 2025-3-25 08:48:55 | 只看該作者
23#
發(fā)表于 2025-3-25 14:12:28 | 只看該作者
24#
發(fā)表于 2025-3-25 18:23:23 | 只看該作者
25#
發(fā)表于 2025-3-25 20:57:07 | 只看該作者
26#
發(fā)表于 2025-3-26 03:46:36 | 只看該作者
Biological Response Modifiers, patients with cancer are not necessarily well prepared for the translation of biotherapy to the clinic. Biotherapeutic approaches are broad and involve a whole range of physiological responses inherent in cancer biology. The approaches needed to bring these biotherapeutic capabilities to the clinic
27#
發(fā)表于 2025-3-26 04:42:33 | 只看該作者
Purine Antimetabolites,imetabolites indeed play a very prominent role. Of 37 experimental anticancer drugs for which INDA’s were filed by the NCI during the period 1977–1983, no less than seven are purine antimetabolites (64). These experimental antipurines are:
28#
發(fā)表于 2025-3-26 11:20:13 | 只看該作者
Alkylating Agents,e selectively towards a tumour cell rather than towards a normal cell. Selectivity of alkylating agent attack towards tumour cells may also be increased by clinical protection measures on normal tissues (e.g., by autologous bone marrow transplantation). The development of alkylating agent use has th
29#
發(fā)表于 2025-3-26 12:52:40 | 只看該作者
Platinum Compounds,0 and P388 leukemias, and human mammary and colon xenographs, among others (212). In addition, DDP was found to be active by several treatment schedules, against rat as well as mouse tumors, and to be active against tumors of both chemical and biological origins (169). Clinical trials of DDP first b
30#
發(fā)表于 2025-3-26 20:24:28 | 只看該作者
Nitrosoureas,nitroso agents (81, 82 and references therein). Structure-activity studies led to the development of chloroethylnitrosoureas and observations that one analog, BCNU,* was curative against L1210 leukemia implanted intracranially or intraperitoneally (51, 105).
 關于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結 SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-21 20:42
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權所有 All rights reserved
快速回復 返回頂部 返回列表
榆中县| 库伦旗| 松江区| 亚东县| 庄河市| 敦化市| 韶山市| 麟游县| 灵石县| 澄城县| 罗平县| 余庆县| 瑞金市| 海阳市| 昌乐县| 乃东县| 新乡县| 邻水| 宜丰县| 张家口市| 辽源市| 涞源县| 石城县| 铁力市| 乐东| 疏附县| 娄底市| 任丘市| 喀什市| 富顺县| 波密县| 徐州市| 黔江区| 湟中县| 肇源县| 陆丰市| 玛纳斯县| 渑池县| 阿图什市| 元朗区| 中宁县|